Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Tai Y, Ma X, Shi W; CameL Study Group. Zhou C, et al. Among authors: wu f. J Thorac Oncol. 2023 May;18(5):628-639. doi: 10.1016/j.jtho.2022.12.017. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646210 Free article. Clinical Trial.
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C, Li X, Zhang J, Su C, Chen X, Cai W, Gao G, Li W, Wu F, Li J, Zhao J, Hu Q, Zhao M, Zhou C, Hirsch FR. Liu S, et al. Among authors: wu f. Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4. Lung Cancer. 2018. PMID: 29748021
EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C, Hirsch FR. Jiang T, et al. Among authors: wu f. Int J Cancer. 2019 May 15;144(10):2605-2612. doi: 10.1002/ijc.31962. Epub 2018 Dec 8. Int J Cancer. 2019. PMID: 30387880 Free article.
Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.
Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F, Ren S, Zhou C. Pan Y, et al. Among authors: wu f. Thorac Cancer. 2019 Apr;10(4):686-694. doi: 10.1111/1759-7714.12986. Epub 2019 Feb 22. Thorac Cancer. 2019. PMID: 30793872 Free PMC article.
13,993 results
You have reached the last available page of results. Please see the User Guide for more information.